Broadfin Capital’s Novavax NVAX Stock Holding History

Broadfin Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-40,000	Closed	-$2.52M	–	67
2013 Q3	$2.52M	Buy	+40,000	New	+$2.25M	0.45%	46

Other funds holding NVAX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Broadfin Capital's NVAX Position: Q4 2013 in Review

Broadfin Capital sold out of Novavax (NVAX) in Q4 2013, closing a stake of 40,000 shares — an estimated $2.52M sold.

Broadfin Capital first reported a position in NVAX in Q3 2013 and held it in 1 quarter. The position peaked at $2.52M in Q3 2013. 129 funds tracked by Wall St. Rank hold NVAX as of Q4 2013.

Broadfin Capital reported no remaining Novavax position as of Q4 2013 after selling out during the quarter.
Broadfin Capital sold 40,000 Novavax shares in Q4 2013, an estimated $2.52M.
Broadfin Capital first reported a position in Novavax in Q3 2013 and held it in 1 quarter.
Broadfin Capital's Novavax position peaked at $2.52M in Q3 2013.
129 funds tracked by Wall St. Rank held Novavax as of Q4 2013.

Based on Broadfin Capital's 13F filing for Q4 2013, filed 14 Feb 2014.